Evaluation of the impact of anticoagulants on the incidence of dementia in patients whit atrial fibrillation: a narrative review
DOI:
https://doi.org/10.11606/issn.1679-9836.v102i4e-203462Keywords:
atrial fibrillation, dementia, anticoagulantAbstract
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with an increased risk of dementia. It is believed that the use of oral anticoagulant drugs is a protective factor for the development of dementia. Thus, this narrative review aimed to present and discuss the current evidence on the impact of anticoagulant use and cognitive impairment in people with AF. Selection was made using the MeSH terms: atrial fibrillation; dementia; treatment; anticoagulants. Inclusion criteria were randomized clinical trials and prospective cohorts published between 2015 and 2021, developed with human beings. 155 articles were identified, 10 of which met the inclusion criteria. Most of the studies analyzed observed a decrease in the risk of dementia whit the use of NOACs (new oral anticoagulants) in relation to the use of warfarin. The study by Kim et al (2021) points out rivaroxaban as the most efficient drug to reduce the risk of dementia, among the NOACs. However, Søgaard et al (2019) showed a higher risk of dementia associated with the use of NOACs, when compared to warfarin. It is concluded that the NOACs and warfarin, decrease the risk of cognitive impairment and dementia in people with AF. However, it is not possible to state the best treatment currently offered.
Downloads
References
Mann D, Zipes DP, Libby P, Bonow RO. Braunwald: Tratado de doenças cardiovasculares. 10ª ed. Rio de Janeiro: Elsevier Editora Ltda; 2018. v.2.
Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217-21. doi:10.1177/1747493019897870.
Vlachos K, Letsas KP, Korantzopoulos P, Liu T, Georgopoulos S, Bakalakos A, et. al. Prediction of atrial fibrillation development and progression: Current perspectives. World J Cardiol. 2016;8(3):267-76. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807315/.
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612.
Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003 May 21;41(10):1690-6. doi: 10.1016/s0735-1097(03)00332-2. https://www.sciencedirect.com/science/article/pii/S0735109703003322?via%3Dihub.
Sanders A, Absher J, Shugarman S, Nininger J, Bennett A, Roca R. Quality improvement in neurology: dementia management quality measurement set update. Neurology. 2017;88(20):1951-7. https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.17401?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.
Dening T, Sandilyan MB. Dementia: definitions and types. Nurs Stand. 2015;29(37):37-42. https://pubmed.ncbi.nlm.nih.gov/25967445/.
O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698-706. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00463-8/fulltext.
Wolters FJ, Ikram MA. Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol. 2019;39(8):1542-9. https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.119.311908?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org.
Ott A, Breteler MM, Bruyne MC, Harskamp F, Grobbee DE, Horman A. Atrial fibrillation and dementia in a population-based study: the rotterdam study. Stroke. 1997;28(2):316-21. https://www.ahajournals.org/doi/10.1161/01.str.28.2.316?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.
Aldrugh S, Sardana M, Henninger N, Saczynski JS, McManus DD. Atrial fibrillation, cognition and dementia: a review. J Cardiovasc Electrophysiol. 2017;28(8):958–65. https://www.ncbi.nlm.nih
Danese E, Montagnana M, Cervellin G, Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. Ann Med. 2014;46(6):364‐71. https://www.tandfonline.com/doi/full/10.3109/07853890.2014.912835.
Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373(9658):155‐66. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60040-4/fulltext.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. https://pubmed.ncbi.nlm.nih.gov/19762550/.
Søgaard M, Skjøth F, Jensen M, Kjældgaard, JN, Lip, G., Larsen, TB, Nielsen, PB. Nonvitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients and risk of dementia. A nationwide propensity-weighted cohort study. J Amn Heart Assoc. 2019;8(11):e011358. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585353/.
Mongkhon P, Fanning L, Lau WCY, Tse G, Lau KK, Wei L, Kongkaew C, Wong ICK. Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: a population-based cohort study. Heart Rhythm. 2020;17(5 Pt A):706-13. https://www.heartrhythmjournal.com/article/S1547-5271(20)30011-4/fulltext.
Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018;39(6):453-60. https://pubmed.ncbi. nlm.nih.gov/29077849/.
Ding M, Fratiglioni L, Johnell K, et al. Atrial fibrillation, antithrombotic treatment, and cognitive aging: A population-based study. Neurology. 2018;91(19):e1732-e1740. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251601/.
Field TS, Weijs B, Curcio A, Giustozzi M, Sudikas S, Katholing A, Wallenhorst C, Weitz JI, Cohen AT, Martinez C. Incident atrial fibrillation, dementia and the role of anticoagulation: a population-cased cohort study. Thromb Haemost. 2019;119(6):981–91. https://pubmed.ncbi.nlm.nih.gov/30919384/.
Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J. 2019;40(28):2327-35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6642728/
Kim D, Yang PS, Jang E, et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace. 2021;23(2):184-95. https://pubmed.ncbi.nlm.nih.gov/33063123/.
Wändell P, Carlsson AC, Sundquist J, et al. Antihypertensive drugs and relevant cardiovascular pharmacotherapies and the risk of incident dementia in patients with atrial fibrillation. Int J Cardiol. 2018;1(272):149-54. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690390/.
Mailhot T, McManus DD, Waring ME, et al. Frailty, cognitive impairment, and anticoagulation among older adults with nonvalvular atrial fibrillation. J Am Geriatr Soc. 2020;68(12):2778-86. https://www.ncbi.nlm.nih. gov/pmc/articles/PMC8567309/.
Hyogo K, Yoshida A, Takeuchi M, et al; One-year clinical outcomes of anticoagulation therapy among Japanese patients with atrial fibrillation: the Hyogo AF Network (HAF-NET) Registry. J Arrhythm. 2019;35(5):697-708. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6786980/.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Caroline Fonseca Teixeira, Rodrigo Taranto de Reis, Larissa Rodrigues Perrenout Branca, Igor Dutra Braz
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
